| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 242,600 | $1 | $970.4K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 26,780 | $30 | $883.6K |
| J3262 | Injection, tocilizumab, 1 mg | 81,920 | $10 | $409.6K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 31,880 | $10 | $318.8K |
| J9312 | Injection, rituximab, 10 mg | 2,900 | $60 | $182.7K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 5,250 | $30 | $136.5K |
| J0897 | Injection, denosumab, 1 mg | 2,580 | $20 | $46.4K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 680 | $50 | $30.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 340 | $80 | $28.1K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 280 | $50 | $15.2K |